Document:

exv10w4

 

Exhibit 10.4

August 17, 2007

Mr. Robert Bennett

President

Discovery Holdings Company

12300 Liberty Boulevard

Englewood, CO 80112

RE: Sprint Nextel Stock Award

Dear Dob:

I am writing to provide you additional information regarding your recent special equity award. As
you know, on August 7, 2007 the Sprint Nextel Board awarded you a grant of 3,776 shares of Sprint
Nextel common stock, plus a cash payment of $113.46 for dividends that would have been earned. A
check in the amount of $113.46 is enclosed.

Of the 3,776 shares awarded to you, 3,767 shares are for services rendered by you as a Board member
for the time period from the date you joined the Board (October 8, 2006) to the date of the 2007
annual meeting of shareholders (May 8, 2007). Had the current practice of granting restricted
stock units (RSUs) to new directors been in place at the time of your appointment to the Board, you
would have received an RSU award valued at $62,500. This value was determined by dividing the
value of the annual RSU award ($100,000) made to outside directors, by 24 to establish the dollar
value for each half-month of service that a director can provide in a 12-month period ($100,000/24
= $4,166.67). We then multiplied $4,166.67 by the number of half-months of service you provided
between October 8, 2006 and May 8, 2007, which was 15 half-months ($4,166.67 x 15 = $62,500). The
number of shares awarded was then determined by dividing $62,500 by $16.59, which represents the
average 30-calendar day fair market value of Sprint Nextel common stock for the period beginning
August 16, 2006 and ending on September 14, 2006 ($62,500 /$16.59 = 3,767 shares).

The nine additional shares granted to you represent dividends that would have accrued on the 3,767
RSUs for the period from October 8, 2006 to May 8, 2007, which brings the total number of shares of
common stock granted to you to 3,776 shares (3,767 + 9).

The cash payment of $113.46 consists of (1) $19.06, which represents the cash value of fractional
share dividends, and (2) $94.40, which represents the second quarter cash dividends that would have
been paid on the shares had you received an RSU grant that vested on the May 8, 2007 annual meeting
date. These calculations are summarized on the attached worksheet.

 

 

Mr. Robert Bennett

Page 2

August 17, 2007

The amount that we will report on Form 1099-MISC for 2007 relating to this award is $75,255.86 (see
detail below). Your basis in the shares delivered equals $19.90 per share (the closing price of
Sprint Nextel common stock on Monday, August 6, 2007).

	 	 	 	 	 
	 	 	Amount to be	 
	 	 	reported on 2007	 
	 	 	Form 1099-MISC*	 
	3,776 shares of Sprint Nextel common
stock
	 	$	75,142.40	 
	Fractional share cash
	 	$	19.06	 
	2nd Quarter Dividend
Equivalent
	 	$	94.40	 
	 
	 	 	 
	Total
	 	$	75,255.86	 
	 
	 	 	 

 

			
	*	 	None of the amounts are from a qualified plan and therefore are not eligible for
roll-over to a qualified plan.

Per your instructions, these shares will be delivered to UBS. If you do not have access to your
UBS account and you require a statement or information regarding your account, please contact
George Lee, Vice President — Investments at UBS. He can be
reached at (719) 520-XXXX.

As a reminder, our director stock ownership guidelines require our outside directors to hold equity
or equity interests in our common stock with a value of at least $140,000 (which is two times the
annual board retainer amount), and to meet this requirement by the second anniversary of your
election to the board. In addition, minimum holding periods apply to equity and equity interests
acquired by outside directors from Sprint Nextel.

Congratulations on receiving this award. Sprint Nextel truly values the counsel, direction and
judgment of its Board members, and we look forward to working with you to achieve our goals and
objectives.

If you have questions about your equity award or the Director Compensation Program, please feel
free to contact me at (703) 433-XXXX.

My best regards,

Christie A. Hill

Enclosures

cc: Jim Hayesexv10w1

 

Exhibit 10.1

Other Transactions (OT) Agreement/Modification P00001

OTHER TRANSACTION FOR PROTOTYPE AGREEMENT

BETWEEN

GenVec, Inc.

65 West Watkins Mill Road

Gaithersburg, MD 20878

AND

The Department of Homeland Security

Science & Technology Directorate

Washington, DC 20528

	 	 	 
	Agreement Number:

	 	HSHQDC-07-9-00004
	Modification Number:

	 	P00001
	Concerning:

	 	Human Adenovirus Type C, Serotype 5
	Replication Deficient Foot-and-Mouth Disease (FMD) Serotype-Specific Vectore

Vaccines, and Vectored Biological Immunomodulators

	 
	Base Period:
	 
	Total Value of Base Period:

	 	$5,976,726
	GenVec’s Cost Share/Contribution

	 	$0.00
	Government’s Cost Share/Contribution

	 	$5,976,726
	Funds Obligated: $5,976,726

	 	 
	 
	Option 1:

	Total Value of Option 1:

	 	$5,613,815
	GenVec’s Cost Share/Contribution

	 	$0.00
	Government’s Cost Share/Contribution

	 	$5,613,815
	Funds Obligated: $5,613,815

	 	 
	PR Number:

	 	RSCB-07-00200

	Line of Accounting:

	 	NONE000-000-7X-31-01-0 1-002-01-00-0000-00-00-00-0 0-GE-OE-25-11-000000

	Authority:          
Section 831 of the Homeland Security Act of 2002, Public Law 107-296

The Modification of the Agreement is entered into between the United States of America, hereinafter
called the Government, represented by The Department of Homeland Security (DHS), and GenVec, Inc., pursuant to and under US Federal law.

	 	 	 
	FOR GenVec:
	 	
FOR DHS:
	    /s/
 

GenVec/Date	 	    
/s/
 

OT Agreements Officer/Date

AUG 30 2007

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

The following articles are revised as follows:

ARTICLE II: TERM is amended to add the following:

The period of performance of Option 1 of this agreements starts on date of award and ends on 31
January 2008.

ARTICLE III: STATEMENT OF OBJECTIVES is revised to incorporate the following tasks for Option 1:

I. Background

The Department of Homeland Security (DHS) is committed to using cutting edge technologies and
scientific talent in its quest to make America safer. DHS’s Directorate of Science and Technology
(S&T) is tasked with researching and organizing the scientific, engineering, and technological
resources of the United States and leveraging these existing resources into technological tools to
help protect the homeland. In support of this effort, the DHS S&T Plum Island Animal Disease
Center (PIADC) in Long Island, NY, is a unique research facility and critical national asset
conducting research on diseases of livestock to protect America from terrorists threats directed
against agriculture from the intentional introduction of diseases. As defined in Homeland Security
Presidential Directive-7 (HSPD-7) and HSPD-9, the Secretary of Homeland Security is responsible for
coordinating the overall national effort to enhance the protection of the critical infrastructure
and key resources of the United States, including the defense of agriculture and food. To fulfill
these requirements, DHS S&T supports programs at PIADC to strengthen the nation’s ability to
predict and respond to the incursion of a foreign animal disease.

DHS
S&T requires scientific, vaccine development and regulatory services from
GenVec, Inc. (GenVec), GenVec is a non-traditional contractor that has core competencies in patent
protected technology platforms for replication-defective recombinant adenovirus serotype 5(rAd5)
based-vaccines and therapeutic product candidates. GenVec’s technology has been successfully
applied to discovery, pre-clinical, and clinical (Phase I-II) trials for human vaccines. GenVec
also has experience in Ad5 production (scale-up and downstream processing) with an integrated QA
program.

GenVec has held a historical contractual scientific relationship with the USDA ARS on a
Foot-and-Mouth Disease Virus (FMDV) countermeasure R&D program. Specifically, USDA and GenVec
entered into Specific Cooperative Agreements (SCAs) in 2004-2005 and 2005-2006 to use reasonable
commercial efforts to construct, produce and test a rAd5 based vector containing FMDV serotype
empty capsids as part of a Plum Island FMD vaccine and immunomodulator program. These SCAs were
funded through DHS-USDA interagency agreements and DHS S&T scientists have been involved in the
testing and evaluation of several rAd5 based vaccine vectors since 2005. In addition, USDA and
GenVec have been interacting through a Collaborative Research and Development

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

Agreement (CRADA) since 2004. The objective of the CRADA is to jointly construct and test GenVec
Advectors expressing FMD genes and livestock cytokines, and to identify Advectors and complementing
cell lines that have the potential to serve as a viral-vectored platform for a new generation of
FMD vaccines. DHS S&T scientists have participated in the USDA-GenVec CRADA since 2004 through a
DHS-USDA ARS interagency agreement on the joint research and development of FMD countermeasures,
such as FMD vaccines and biological immunomodulators.

Based on the successful technical outcome to date of the base year contract agreement (awarded 1
February 2007) and the initiation and acceleration of pre-product development activities at GenVec
(originally targeted for option year 1) that has resulted in the acceleration of lead FMD vaccine
material for testing, DHS would like to move forward with GenVec and exercise option year 1 to
allow uninterrupted continuation and development of the lead FMD vaccine candidate for eventual
licensing by USDA Center for Veterinary Biologics. These products would be made available for
potential manufacture and procurement by the USDA National Center for Animal Health Emergency
Management National Veterinary Stockpile to help accomplish critical mission objectives with regard
to live FMDV and vaccine countermeasures against high consequence Foreign Animal Diseases such as
those caused by FMDV.

II. Scope of Work

For option year 1, milestone 1*

For option year 1, * milestones 2 and 3 *

For option year 1, milestones 4 and 5 *

For option year 1, milestone 6 *

For option year 1, milestone 7 *

III. Deliverables.

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

See Attachment II for detailed list and description of technical data and physical deliverables
associated with each of the two revised milestones (milestones 1 and 7).

IV. Other Contract Details

	A.	 	Period of Performance. The period of performance for this revised SOW is a base period from
the contract year one option award date to January 31, 2008, with the option to negotiate and
award an additional one (1) one-year period. DHS may give subsequent extension notices to
GenVec, Inc. in writing for further performance in accordance with the terms of this SOW.
	 
	B.	 	Travel. All travel must be approved by the DHS Technical Representative. All foreign travel
must be approved in advance by the ORD Program Manager, DHS Programs, Plans and Budgets (PPB),
and the DHS S&T Special Assistant for International Policy.
	 
	C.	 	DHS-Furnished Information.

	 	i.	 	DHS will provide certain DHS information, materials, and forms unique to DHS
to GenVec, Inc. to support certain tasks under this SOW. Delays in the supply of DHS
information, materials to GenVec could result in delays to the completion of certain
deliverables.
	 
	 	ii.	 	The DHS S&T Technical Representative identified in this SOW will be the point
of contact (POC) for identification of any required information to be supplied by DHS.
	 
	 	iii.	 	GenVec, Inc. will prepare any documentation according to the guidelines
provided by DHS.

	E.	 	Place of Performance. GenVec, Inc. will perform the work under this SOW at their place of
R&D business, located in Gaithersburg, MD and through the use of sub-contractors where
required as identified in this SOW.
	 
	F.	 	DHS-Furnished Property. DHS property will not be provided to GenVec, Inc. unless otherwise
agreed to by the parties of the agreement.
	 
	G.	 	Deliverables. GenVec, Inc. will provide all deliverables identified in this SOW directly to
the DHS S&T Technical Representative with a copy of the transmittal letter to the Other
Transaction Contracting Officer and as otherwise specified in this SOW.

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

	H.	 	Publications. All manuscripts must be approved prior to submission by the DHS S&T Technical
Representative at PIADC and by the GenVec Technical Representative with approval not to be
unreasonably withheld by either party.
	 
	I.	 	Program Status Report. GenVec, Inc. will deliver a quarterly program status reports to the
DHS S&T Technical Representative and DHS S&T Resource Manager containing the following
metrics: (1) monthly scientific reports will be delivered to the DHS S&T Technical
Representative according to mutually agreed upon format and content requirements; and (2) a
monthly report, including financial, schedule, and scope information, risk information and an
assessment of performance will be delivered to the DHS S&T Technical Representative and the
DHS S&T Resource Manager. Financial data should include monthly expenditures for labor,
travel and equipment.
	 
	J.	 	Security Requirements. All work performed under this SOW is unclassified unless otherwise
specified by DHS. If classified work is required under this SOW, DHS will provide specific
guidance to the contractor as to which work will be conducted in a classified manner and at
which classification level. GenVec, Inc. participants will also adhere to applicable
government orders, guides, and directives while performing the work hereunder.

V. Points of Contact

GenVec, Inc. Points of Contact (POCs) are as follows:

	 	•	 	Technical POC(s) —

*

65 West Watkins Road

Gaithersburg, MD 20878

Phone: *

*
	 
	 	•	 	Financial POC(s) —

*

65 West Watkins Road

Gaithersburg, MD 20878

Phone: *

*

The DHS POCs are as follows:

	 	•	 	DHS S&T Technical Representative —

	 	 	 	*

Ag Program Manager

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

	 	 	 	Department of Homeland Security

ATTN: Science and Technology Directorate

Washington, DC 20528

*

*

	 	•	 	Resource Manager

	 	 	 	*
Department of Homeland Security

ATTN: Science and Technology Directorate/Office, *

Washington, DC 20528

*

*

	 	 	 	Either party may change its representatives named in this Statement of Work by written
notification to the other Party. The Government will effect the change as stated in subparagraph
C.4 of Article IV of the Other Transaction Agreement.

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

ATTACHMENT I — STATEMENT OF WORK EXECUTION (Option Year 1)

Milestone 1: *

General Approach

*

Adenovector Construction

*

Figure 1 *

Figure 2 *

Figure 3 *

Figure 4 *

Sequencing to Confirm Construction

*

Description of FMD Adenoviral Vaccine Vectors

*

cGMP Vector * Production and Characterization

*

Table 2: *

* Development Studies (New Funding Activity Option year 1)

*

* Potency Studies (New Funding Activity Option Year 1)

*

Milestone 7 — *

Table 9: *

Key Programmatic Steps

*

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

Description of * Process

*

Description of GenVec * Program

*

Description of GenVec * Program

*

Conduct * studies in advance of full development process *. Provide material to DHS * testing
(New Funding Activity Option Year 1).

*

SOW ATTACHMENT II — LIST OF TECHNICAL AND PHYSICAL

DELIVERABLES

(OPTION YEAR ONE)

*

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

 

 

ARTICLE IV: PAYABLE EVENT SCHEDULE AND DELIVERABLES is
amended to add the following:

B. Schedule of Payments and Payable Milestones (Phase IIIa):

	 	 	 	 	 
	Milestone	 	Option 1	 	Milestone Date
	 	 	Amount	 	 
	1	 	*	 	*
	2	 	*	 	*
	3	 	*	 	*
	4	 	*	 	*
	5	 	*	 	*
	6	 	*	 	*
	7	 	*	 	*

All other ARTICLES in the agreement remain unchanged and remain in effect during this Option 1
effort.

 

			
	*	 	The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]